{"nctId":"NCT00236938","briefTitle":"Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis","startDateStruct":{"date":"2002-07"},"conditions":["Anemia"],"count":121,"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","interventionNames":["Drug: Venofer and stable erythropoietin (EPO) regimen"]},{"label":"Group B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: stable erythropoietin (EPO) regimen"]}],"interventions":[{"name":"Venofer and stable erythropoietin (EPO) regimen","otherNames":["Iron Sucrose"]},{"name":"stable erythropoietin (EPO) regimen","otherNames":["EPO"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hemoglobin \\>= 9.5 and \\<= 11.5 g/dL.\n* Ferritin \\<= 500 ng/ml.\n* Serum Transferrin Saturation (TSAT) \\<= 25%.\n* Stable erythropoietin (EPO) Regimen for 8 weeks.\n* No iron for last 4 weeks before randomization.\n\nExclusion Criteria:\n\n* Known Sensitivity to Iron Sucrose.\n* Suffering concomitant severe diseases of the liver \\& cardiovascular system.\n* Pregnancy / Lactation.\n* Inadequate dialysis.\n* Current treatment for asthma.\n* Significant blood loss.\n* Probability of need for transfusion or transfusion within 1 week of enrollment.\n* Anticipated major surgery.\n* Hemochromatosis / hemosiderosis.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline to the Highest Hemoglobin up to Day 71","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.10"},{"groupId":"OG001","value":".7","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to the Highest Serum Transferrin Saturation (TSAT) up to Day 71","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.176","spread":"15.53"},{"groupId":"OG001","value":"10.383","spread":"12.27"}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to the Highest Ferritin up to Day 71","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"545.05","spread":"585.8"},{"groupId":"OG001","value":"70.523","spread":"159.7"}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to the Highest Reticulocyte Count up to Day 71","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7226","spread":"1.36"},{"groupId":"OG001","value":"0.4630","spread":"1.01"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":75},"commonTop":["Oedema peripheral","Diarrhea NOS","Hypertension NOS","Catheter site infection","Peritoneal infection"]}}}